|
1
|
Govinden R and Bhoola KD: Genealogy,
expression, and cellular function of transforming growth factor-β.
Pharmacol Ther. 98:257–265. 2003.
|
|
2
|
Dubois CM, Laprise MH, Blanchette F,
Gentry LE and Leduc R: Processing of transforming growth factor β1
precursor by human furin convertase. J Biol Chem. 270:10618–10624.
1995.
|
|
3
|
Taylor AW: Review of the activation of
TGF-β in immunity. J Leukocyte Biol. 85:29–33. 2009.
|
|
4
|
Annes JP, Chen Y, Munger JS and Rifkin DB:
Integrin αVβ6-mediated activation of latent
TGF-β requires the latent TGF-β binding protein-1. J Cell Biol.
165:723–734. 2004.
|
|
5
|
Annes JP, Munger JS and Rifkin DB: Making
sense of latent TGF-β activation. J Cell Sci. 116:217–224.
2003.PubMed/NCBI
|
|
6
|
Nakamura K, Kitani A, Fuss I, Pedersen A,
Harada N, Nawata H and Strober W: TGF-β1 plays an important role in
the mechanism of CD4+CD25+ regulatory T cell
activity in both humans and mice. J Immunol. 172:834–842. 2004.
|
|
7
|
Chen ML, Yan BS, Bando Y, Kuchroo VK and
Weiner HL: Latency-associated peptide identifies a novel
CD4+CD25+ regulatory T cell subset with TGF
β-mediated function and enhanced suppression of experimental
autoimmune encephalomyelitis. J Immunol. 180:7327–7337.
2008.PubMed/NCBI
|
|
8
|
Li MO, Wan YY, Sanjabi S, Robertson AK and
Flavell RA: Transforming growth factor-β regulation of immune
responses. Annu Rev Immunol. 24:99–146. 2006.
|
|
9
|
Wrzesinski SH, Wan YY and Flavell RA:
Transforming growth factor-β and the immune response: implications
for anticancer therapy. Clin Cancer Res. 13:5262–5270. 2007.
|
|
10
|
McCartney-Francis NL and Wahl SM:
Transforming growth factor-β: a matter of life and death. J
Leukocyte Biol. 55:401–409. 1994.
|
|
11
|
Shull MM, Ormsby I, Kier AB, et al:
Targeted disruption of the mouse transforming growth factor-β1 gene
results in multifocal inflammatory disease. Nature. 359:693–699.
1992.
|
|
12
|
Kulkarni AB, Huh CG, Becker D, et al:
Transforming growth factor-β1 null mutation in mice causes
excessive inflammatory response and early death. Proc Natl Acad Sci
USA. 90:770–774. 1993.
|
|
13
|
Walsh NC, Crotti TN, Goldring SR and
Gravallese EM: Rheumatic diseases: the effects of inflammation on
bone. Immunol Rev. 208:228–251. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Muñoz-Valle JF, Torres-Carrillo NM,
Guzmán-Guzmán IP, et al: The functional class evaluated in
rheumatoid arthritis is associated with soluble TGF-β1 serum levels
but not with G915C (Arg25Pro) TGF-β1 polymorphism. Rheumatol Int.
32:367–372. 2012.PubMed/NCBI
|
|
15
|
Kim SY, Han SW, Kim GW, Lee JM and Kang
YM: TGF-β1 polymorphism determines the progression of joint damage
in rheumatoid arthritis. Scand J Rheumatol. 33:389–394. 2004.
|
|
16
|
Lafyatis R, Thompson NL, Remmers EF, et
al: Transforming growth factor-β production by synovial tissues
from rheumatoid patients and streptococcal cell wall arthritic
rats. Studies on secretion by synovial fibroblast-like cells and
immunohistologic localization. J Immunol. 143:1142–1148. 1989.
|
|
17
|
Mantel PY and Schmidt-Weber CB:
Transforming growth factor-β: recent advances on its role in immune
tolerance. Methods Mol Biol. 677:303–338. 2011.
|
|
18
|
Wang TY, Li J, Li CY, Jin Y, Lü XW, Wang
XH and Zhou Q: Leflunomide induces immunosuppression in
collagen-induced arthritis rats by upregulating
CD4+CD25+ regulatory T cells. Can J Physiol
Pharm. 88:45–53. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim JS, Kim JG, Moon MY, Jeon CY, Won HY,
Kim HJ, Jeon YJ, Seo JY, Kim JI, Kim J, Lee JY, Kim PH and Park JB:
Transforming growth factor-beta1 regulates macrophage migration via
RhoA. Blood. 108:1821–1829. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Henson PM and Riches DW: Modulation of
macrophage maturation by cytokines and lipid mediators: a potential
role in resolution of pulmonary inflammation. Ann NY Acad Sci.
725:298–308. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Grenier D and Grignon L: Response of human
macrophage-like cells to stimulation by Fusobacterium
nucleatum ssp nucleatum lipopolysaccharide. Oral
Microbiol Immunol. 21:190–196. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang N, Wu LL, Nikolic-Paterson DJ, et al:
Local macrophage and myofibroblast proliferation in progressive
renal injury in the rat remnant kidney. Nephrol Dial Transplant.
13:1967–1974. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Takaki H, Minoda Y, Koga K, et al: TGF-β1
suppresses IFN-γ-induced NO production in macrophages by
suppressing STAT1 activation and accelerating iNOS protein
degradation. Genes Cells. 11:871–882. 2006.
|
|
24
|
Rodenburg RJ, van Den Hoogen FH, Barrera
P, van Venrooij WJ and van De Putte LB: Superinduction of
interleukin 8 mRNA in activated monocyte derived macrophages from
rheumatoid arthritis patients. Ann Rheum Dis. 58:648–652. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vodovotz Y: Control of nitric oxide
production by transforming growth factor-β1: mechanistic insights
and potential relevance to human disease. Nitric Oxide. 1:3–17.
1997.
|
|
26
|
Jun CD, Choi BM, Kim SU, Lee SY, Kim HM
and Chung HT: Down-regulation of transforming growth factor-β gene
expression by antisense oligodeoxynucleotides increases recombinant
interferon-γ-induced nitric oxide synthesis in murine peritoneal
macrophages. Immunology. 85:114–119. 1995.
|
|
27
|
Ding A, Nathan CF, Graycar J, Derynck R,
Stuehr DJ and Srimal S: Macrophage deactivating factor and
transforming growth factors-β1 -β2 and -β3 inhibit induction of
macrophage nitrogen oxide synthesis by IFN-γ. J Immunol.
145:940–944. 1990.
|
|
28
|
Tsunawaki S, Sporn M, Ding A and Nathan C:
Deactivation of macrophages by transforming growth factor-β.
Nature. 334:260–262. 1988.
|
|
29
|
Lee GT, Hong JH, Kwak C, Woo J, Liu V, Lee
C and Kim IY: Effect of dominant negative transforming growth
factor-β receptor type II on cytotoxic activity of RAW 264.7, a
murine macrophage cell line. Cancer Res. 67:6717–6724. 2007.
|
|
30
|
McCartney-Francis NL and Wahl SM:
Dysregulation of IFN-γ signaling pathways in the absence of TGF-β1.
J Immunol. 169:5941–5947. 2002.
|
|
31
|
Bogdan C, Röllinghoff M and Diefenbach A:
The role of nitric oxide in innate immunity. Immunol Rev.
173:17–26. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cook HT and Cattell V: Role of nitric
oxide in immune-mediated diseases. Clin Sci (Lond). 91:375–384.
1996.PubMed/NCBI
|
|
33
|
Wang JX, Hou LF, Yang Y, Tang W, Li Y and
Zuo JP: SM905, an artemisinin derivative, inhibited NO and
pro-inflammatory cytokine produced by suppressiong MAPK and NF-κB
pathways in RAW 264.7 macrophages. Acta Pharmacol Sin.
30:1428–1435. 2009.PubMed/NCBI
|
|
34
|
Uematsu S and Akira S: Toll-like receptors
and innate immunity. J Mol Med. 9:712–725. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kawai T, Takeuchi O, Fujita T, et al:
Lipopolysaccharide stimulates the MyD88-independent pathway and
results in activation of IFN-regulatory factor 3 and the expression
of a subset of lipopolysaccharide-inducible genes. J Immunol.
167:5887–5894. 2001. View Article : Google Scholar
|
|
36
|
Takeda K and Akira S: Toll-like receptors
in innate immunity. Int Immunol. 17:1–14. 2005. View Article : Google Scholar
|
|
37
|
Chávez-Sánchez L, Chávez-Rueda K,
Legorreta-Haquet MV, et al: The activation of CD14, TLR4, and TLR2
by mmLDL induces IL-1β, IL-6, and IL-10 secretion in human
monocytes and macrophages. Lipids Health Dis. 9:1172010.PubMed/NCBI
|
